Only in Titles

Search results for: receptor

paperclip

#36484974   2022/12/09 To Up

A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection.

The causative agent of CoV disease 2019 is a new coronavirus CoV type 2, affecting the respiratory tract with severe manifestations (SARS-CoV-2). Covid-19 is mainly symptomless, with slight indications in about 85% of the affected cases. Many efforts were done to face this pandemic by testing different drugs and agents to make treatment protocols in different countries. However, the use of these proposed drugs is associated with the development of adverse events. Remarkably, the successive development of SARS-CoV-2 variants which could affect persons even they were vaccinated, prerequisite wide search to find efficient and safe agents to face SARS-CoV-2 infection. Obeticholic acid (OCA), which has anti-inflammatory effects, may efficiently treat Covid-19. Thus, the goal of this perspective study is to focus on the possible medicinal effectiveness in managing Covid-19. OCA is a powerful farnesoid X receptor (FXR) agonist possessing marked antiviral and anti-inflammatory effects. FXR is dysregulated in Covid-19 resulting in hyper-inflammation with concurrent occurrence of hypercytokinemia. Interestingly, OCA inhibits the reaction between this virus and angiotensin-converting enzyme type 2 (ACE2) receptors. FXR agonists control the expression of ACE2 and the inflammatory signaling pathways in this respiratory syndrome, which weakens the effects of Covid-19 disease and accompanied complications. Taken together, FXR agonists like OCA may reveal both direct and indirect impacts in the modulation of immune reaction in SARS-CoV-2 conditions. It is highly recommended to perform many investigations regarding different phases of the discovery of new drugs.
Gaber El-Saber Batiha, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Fadia S Youssef, Suzy A El-Sherbeni, Walaa A Negm

1388 related Products with: A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection.

1 G 1 G100 mg 100 G25 mg 100 G1 g 25 G 5 G5 mg5 g2 g

Related Pathways

paperclip

#36484969   2022/12/09 To Up

Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.

Daridorexant is a dual orexin receptor antagonist for the treatment of insomnia. In two phase III, 12-week studies in patients with insomnia disorder, daridorexant improved sleep and daytime functioning while maintaining a favorable safety profile. The objective of this 40-week extension study was to assess the long-term safety and tolerability of daridorexant.
Dieter Kunz, Yves Dauvilliers, Heike Benes, Diego García-Borreguero, Giuseppe Plazzi, Dalma Seboek Kinter, Preciosa Coloma, Magdalene Rausch, Mouna Sassi-Sayadi, Stephen Thein

1942 related Products with: Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.

100 ug100 μg 0.1 mg 100 μg100 μg100 μg100 μg100 μg50 100 μg100 μg100 ug

Related Pathways

paperclip

#36484960   2022/12/09 To Up

Obstructive sleep apnea-increased DEC1 regulates systemic inflammation and oxidative stress that promotes development of pulmonary arterial hypertension.

Obstructive sleep apnea (OSA), characterized by chronic intermittent hypoxia (CIH), is a common risk factor for pulmonary arterial hypertension (PAH). As a hypoxia-induced transcription factor, differentially expressed in chondrocytes (DEC1) negatively regulates the transcription of peroxisome proliferative activated receptor-γ (PPARγ), a recognized protective factor of PAH. However, whether and how DEC1 is associated with PAH pathogenesis remains unclear. In the present study, we found that DEC1 was increased in lungs and pulmonary arterial smooth muscle cells (PASMCs) of rat models of OSA-associated PAH. Oxidative indicators and inflammatory cytokines were also elevated in the blood of the rats. Similarly, hypoxia-treated PASMCs displayed enhanced DEC1 expression and reduced PPARγ expression in vitro. Functionally, DEC1 overexpression exacerbated reactive oxygen species (ROS) production and the expression of pro-inflammatory cytokines (such as TNFα, IL-1β, IL-6, and MCP-1) in PASMCs. Conversely, shRNA knockdown of Dec1 increased PPARγ expression but attenuated hypoxia-induced oxidative stress and inflammatory responses in PASMCs. Additionally, DEC1 overexpression promoted PASMC proliferation, which was drastically attenuated by a PPARγ agonist rosiglitazone. Collectively, these results suggest that hypoxia-induced DEC1 inhibits PPARγ, and that this is a predominant mechanism underpinning oxidative stress and inflammatory responses in PASMCs during PAH. DEC1 could be used as a potential target to treat PAH.
Xiaoming Li, Xiang Zhang, Xiaozhi Hou, Xin Bing, Fangyuan Zhu, Xinhao Wu, Na Guo, Hui Zhao, Fenglei Xu, Ming Xia

2199 related Products with: Obstructive sleep apnea-increased DEC1 regulates systemic inflammation and oxidative stress that promotes development of pulmonary arterial hypertension.

164 Arrays/Slide200ug8 Sample Kit10 mg12100ug4 Membranes/Box

Related Pathways

paperclip

#36484959   2022/12/09 To Up

Identification of the Genetic Association Between Type-2-Diabetes and Pancreatic Cancer.

Type-2-diabetes (T2D) and pancreatic cancer (PC) are both common diseases globally. Although T2D is reported as the adverse factor for predicting PC prognosis, its pathophysiology and relation with PC remain unknown. This study focused on exploring differentially expressed genes (DEGs) as well as their functional roles in T2D and PC, aiming to reveal the underlying association between the T2D and PC. To identify DEGs in T2D and PC, this study analyzed four microarray datasets obtained from Gene Expression Omnibus (GEO) database. Then, this work carried out enrichment as well as protein-protein interaction (PPI) network analysis for exploring DEGs-enriched functions and pathway. Besides, expression of hub genes was explored. TISIDB database was adopted to analyze the correlations among key gene and immune characteristics. Finally, the key gene expression was confirmed in vitro. DEGs were first screened from gene expression profiles of T2D and PC datasets, respectively. Then 135 common genes were identified in these four datasets. Based on functional analysis, common DEGs were mostly related to hormone secretion and metabolism pathways. Four hub genes were up-regulated, among which, MAFB was the most significant potential biomarker for PC. MAFB expression was strongly correlated with chemokines, chemokine receptors and immunomodulators. Finally, RT-qPCR was conducted to demonstrate the MAFB expression in T2D and PC. This study identified 15 hub genes with significant effects on the association of T2D with PC, and MAFB gene might be a biomarker for PC and had potential treatment value for PC.
Yaling Liang, Wei Chen, Yun Tang, Meijuan Chen

1187 related Products with: Identification of the Genetic Association Between Type-2-Diabetes and Pancreatic Cancer.

96T96T

Related Pathways

paperclip

#36484868   2022/12/09 To Up

Epstein-Barr virus-associated inflammatory pseudotumor variant of follicular dendritic cell sarcoma of the liver: a case report and review of the literature.

Follicular dendritic cell sarcoma is a rare stromal tumor with no standard treatment. However, some reports have revealed that follicular dendritic cell sarcoma has an inflammatory pseudotumor variant associated with Epstein-Barr virus infection that has a relatively good prognosis. In this report, we present a case of a resected inflammatory pseudotumor variant of follicular dendritic cell sarcoma of the liver, and have reviewed the literature on the clinicopathological, molecular, and genomic features of this tumor.
K Abe, M Kitago, S Matsuda, M Shinoda, H Yagi, Y Abe, G Oshima, S Hori, Y Endo, T Yokose, E Miura, N Kubota, A Ueno, Y Masugi, H Ojima, M Sakamoto, Y Kitagawa

1485 related Products with: Epstein-Barr virus-associated inflammatory pseudotumor variant of follicular dendritic cell sarcoma of the liver: a case report and review of the literature.

25 200 200 25

Related Pathways

paperclip

#36484801   2022/12/09 To Up

Synthesis, Characterization, and Application of Muscarinergic M Receptor Ligands Linked to Fluorescent Dyes.

Through the linkage of two muscarinergic M receptor ligands to fluorescent tetramethylrhodamine- and cyanine-5-type dyes, two novel tool compounds, OFH5503 and OFH611, have been developed. Based on the suitable binding properties and kinetics related to the M subtype, both ligand-dye conjugates were found to be useful tools to determine binding affinities via flow cytometric measurements. In addition, confocal microscopy underlined the comparably low unspecific binding and the applicability for studying M receptor expression in cells. Along with the proven usefulness regarding studies on the M subtype, the conjugates OFH5503 and OFH611 could, due to their high affinity to the M receptor, evolve as even more versatile tools in the field of research on muscarinergic receptors.
Johannes Köckenberger, Oliver Fischer, Andreas Konopa, Sebastian Bergwinkl, Susanne Mühlich, Peter Gmeiner, Roger Jan Kutta, Harald Hübner, Max Keller, Markus R Heinrich

2592 related Products with: Synthesis, Characterization, and Application of Muscarinergic M Receptor Ligands Linked to Fluorescent Dyes.

50ul0.1ml (1mg/ml)100ug Lyophilized0.1ml50ul (1mg/ml)100ug100ug Lyophilized100ug Lyophilized100ug Lyophilized50ul50ul

Related Pathways

paperclip

#36484754   // To Up

[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].

PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibition has proven its interest to potentiate the cholesterol-lowering effects of statins. Indeed, this protein contributes to the intracellular degradation of LDL cholesterol receptors and thereby reduces their recycling and expression at the hepatocyte membrane. PCSK9 inhibition allows a major and sustained reduction of LDL cholesterol (LDL-c) in patients with familial hypercholesterolaemia or with established cardiovascular disease. Two monoclonal antibodies that inhibit the effect of PCSK9 are currently commercialized, alirocumab and evolocumab. Another approach consists in the inhibition of PCSK9 synthesis. Inclisiran is a novel small interfering RNA-based therapy (anti-sense). By binding to the messenger RNA (mRNA) precursor of PCSK9, inclisiran inhibits the PCSK9 gene expression, resulting in increased hepatocyte recycling and membrane expression of LDL receptors and decreased levels of LDL-c. This article summarizes the mode of action, pharmacokinetics, efficacy, safety profile, indications and reimbursement conditions of inclisiran. This novel cholesterol-lowering drug is indicated as add-on therapy in adults with atherosclerotic cardiovascular disease or with heterozygous familial hypercholesterolaemia in whom LDL-c level is ? 100 mg/dl and does not reach target LDL-c levels despite statin and ezetimibe or without statin or ezetimibe in case of intolerance or contra-indication for one of these medications.
A J Scheen, C Wallemacq, P Lancellotti

2523 related Products with: [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].

500 tests0.1 mg1 kit96 wellsOne 96-Well Microplate Ki1 kit96T

Related Pathways

paperclip

#36484751   // To Up

[Timing of gonadectomy in patients with complete androgen insensitivity syndrome].

Complete androgen insensitivity syndrome is the most frequent cause of disorder of sexual development in 46 XY patients. It is caused by mutations of the AR gene coding for the androgen receptor. Transmission is X-linked and mutations are most of the time inherited. It leads to a complete lack of response to androgen resulting in the presence of female external genitalia in 46 XY patients, normal but undescended testes and lack of female internal genitalia due to the secretion of anti-Müllerian hormone by male gonads. Traditionally, gonadectomy was proposed before puberty to decrease the risk of gonadal malignancy. However, more recent studies underlined the benefits of postponing gonadectomy until after pubertal development. Benefits of deferred gonadectomy are spontaneous pubertal development through peripheral aromatization of testosterone into oestrogens and the chance for the patient to have an active role in the decision-making process. After gonadectomy, hormone replacement therapy is required in order to prevent complications due to hypogonadism such as osteoporosis, cardiovascular diseases and a reduction of life expectancy.
T Vereecken, A S Parent, C Van Linthout, M Laterre, J Fudvoye, V Nechifor, M Demarche, A Pintiaux

2085 related Products with: [Timing of gonadectomy in patients with complete androgen insensitivity syndrome].

100 μg100 μg2.5 mg1 set (5 x 1 ml)5 mg50 ug50 mg96 wells (1 kit)5

Related Pathways

paperclip

#36484747   // To Up

[CAR-T cells therapy in solid tumors : where are we now ?].

Chimeric antigen receptor T cells (also known as CAR-T cells) have already made their way into the therapeutic arsenal of specific hematological cancers, significantly improving the prognosis of patients. The prospect of such an innovative and effective treatment in solid tumors is very attractive. For this reason, several clinical studies have been initiated. Unfortunately, the antigenic heterogeneity and microenvironmental hostility of these solid tumors currently limit the effectiveness of CAR-T cells. New strategies are being sought to counteract these therapeutic obstacles.
F Troisfontaine, C Denis, S Servais, L Lousberg, G Jerusalem

1017 related Products with: [CAR-T cells therapy in solid tumors : where are we now ?].

96 wells96 wells96 wells (1 kit)96 wells (1 kit)96 wells (1 kit)96 tests96 wells (1 kit)96 wells (1 kit)96 tests96 wells

Related Pathways

paperclip

#36484738   2022/12/09 To Up

Dietary restriction in senolysis and prevention and treatment of disease.

Aging represents a key risk factor for a plethora of diseases. Targeting detrimental processes which occur during aging, especially before onset of age-related disease, could provide drastic improvements in healthspan. There is increasing evidence that dietary restriction (DR), including caloric restriction, fasting, or fasting-mimicking diets, extend both lifespan and healthspan. This has sparked interest in the use of dietary regimens as a non-pharmacological means to slow aging and prevent disease. Here, we review the current evidence on the molecular mechanisms underlying DR-induced health improvements, including removal of senescent cells, metabolic reprogramming, and epigenetic rejuvenation.
Sepideh Aminzadeh-Gohari, Barbara Kofler, Chiara Herzog

1620 related Products with: Dietary restriction in senolysis and prevention and treatment of disease.

96 tests100ug1-99 mg/ml/ea price x 210 mg 5 G100ul1 ml2.5 mg1,000 tests2.5 mg

Related Pathways